Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15447554 | 1.00 | ACHE (0.45) | ACHEAAK1HTR2AHTR2CHTR2B | |
| SCHEMBL31730506 | 0.90 | SRD5A1 (0.38) | ACHEAAK1 | |
| SCHEMBL803170 | 0.85 | ACHE (0.41) | ACHE | |
| SCHEMBL484696 | 0.84 | ACHE (0.44) | ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL15447555 | 0.82 | ACHE (0.43) | ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL485030 | 0.82 | ACHE (0.43) | ACHE | |
| SCHEMBL485031 | 0.82 | ACHE (0.43) | ACHE | |
| SCHEMBL191810 | 0.82 | ALDH1A1 (0.50) | ACHE | |
| SCHEMBL29496189 | 0.82 | ALDH1A1 (0.50) | ACHE | |
| SCHEMBL19960654 | 0.82 | ALDH1A1 (0.50) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | ACHE 2116/4885AAK1 4153/4885HTR2A 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.